Have Insiders Been Selling Audentes Therapeutics, Inc. (NASDAQ:BOLD) Shares This Year?

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So we’ll take a look at whether insiders have been buying or selling shares in Audentes Therapeutics, Inc. (NASDAQ:BOLD).

What Is Insider Selling?

It’s quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, most countries require that the company discloses such transactions to the market.

We don’t think shareholders should simply follow insider transactions. But it is perfectly logical to keep tabs on what insiders are doing. For example, a Harvard University study found that ‘insider purchases earn abnormal returns of more than 6% per year.’

See our latest analysis for Audentes Therapeutics

Audentes Therapeutics Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider sale was by Lead Independent Director Louis Lange for US$540k worth of shares, at about US$22.49 per share. That means that even when the share price was below the current price of US$39.02, an insider wanted to cash in some shares. Even though it doesn’t necessarily mean anything, that’s certainly not a positive sign, in our book. As a general rule we consider it to be discouraging when insiders are selling below the current price. Please note, however, that this single sale was just 6.1% of Louis Lange’s stake. The only individual insider seller over the last year was Louis Lange.

You can see the insider transactions (by individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

NasdaqGM:BOLD Recent Insider Trading, March 30th 2019
NasdaqGM:BOLD Recent Insider Trading, March 30th 2019

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Does Audentes Therapeutics Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Audentes Therapeutics insiders own about US$27m worth of shares. That equates to 1.6% of the company. We’ve certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Do The Audentes Therapeutics Insider Transactions Indicate?

There haven’t been any insider transactions in the last three months — that doesn’t mean much. Our analysis of Audentes Therapeutics insider transactions leaves us cautious. But it’s good to see that insiders own shares in the company. Of course, the future is what matters most. So if you are interested in Audentes Therapeutics, you should check out this free report on analyst forecasts for the company.

If you would prefer to check out another company — one with potentially superior financials — then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.